KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study
Michael Wang(St. Joseph Health System), Patrick M. Reagan(University of Rochester), Rajul K. Jain(Amgen (United States)), Frederick L. Locke(Moffitt Cancer Center), Marie José Kersten(Hovon), Caron A. Jacobson(Dana-Farber Cancer Institute), John M. Pagel(University of Washington), Arati V. Rao(The University of Texas MD Anderson Cancer Center), John M. Timmerman(Sheba Medical Center), Samantha Jaglowski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), David B. Miklos(Stanford University), André Goy(Hackensack University Medical Center), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Lianqing Zheng(Florida State University), Houston Holmes(Texas Oncology), Peter A. McSweeney(Mesoblast (United States)), Weimin Peng(The University of Texas MD Anderson Cancer Center), Ian W. Flinn(Tennessee Oncology), John M. Rossi(Amgen (United States)), Brian T. Hill(Cleveland Clinic)
Cited by 6
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k